Karyopharm Therapeutics's market cap is currently ―. The company's EPS TTM is $-1.252; its P/E ratio is -0.93; Karyopharm Therapeutics is scheduled to report earnings on May 2, 2024, and the estimated EPS forecast is $-0.33. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22
Income Statement	-
Total Revenue	$ 33.75M	$ 36.01M	$ 37.58M	$ 38.70M	$ 33.58M
Gross Profit	$ 32.26M	$ 35.10M	$ 36.38M	$ 37.35M	$ 30.29M
EBIT	-	$ -28.42M	$ -26.72M	$ -28.31M	$ -33.88M
EBITDA	-	$ -29.07M	$ -27.46M	$ -28.95M	$ -34.02M
Net Income Common Stockholders	$ -41.84M	$ -34.51M	$ -32.63M	$ -34.13M	$ -38.51M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 191.44M	$ 208.31M	$ 237.33M	$ 261.23M	$ 279.03M
Total Assets	$ 240.44M	$ 269.96M	$ 297.83M	$ 324.95M	$ 358.17M
Total Debt	$ 177.02M	$ 177.56M	$ 178.08M	$ 178.59M	$ 179.07M
Net Debt	$ -14.43M	$ -30.75M	$ -59.25M	$ -82.64M	$ -99.96M
Total Liabilities	$ 376.64M	$ 370.36M	$ 369.08M	$ 370.97M	$ 402.11M
Stockholders Equity	$ -136.21M	$ -100.40M	$ -71.25M	$ -45.17M	$ 27.28M
Cash Flow	-
Free Cash Flow	-	$ -29.53M	$ -25.70M	$ -18.91M	-
Operating Cash Flow	$ -18.59M	$ -29.53M	$ -25.70M	$ -18.91M	-
Investing Cash Flow	$ 26.84M	$ -7.68M	$ 21.17M	$ -32.39M	-
Financing Cash Flow	$ 264.00K	-	$ 860.00K	-	-

Currency in USD

Karyopharm Therapeutics Earnings and Revenue History

Income Statement >

Karyopharm Therapeutics Debt to Assets

Balance Sheet >

Karyopharm Therapeutics Cash Flow

Cash Flow >

Karyopharm Therapeutics Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing